OnKure Therapeutics, Inc. (OKUR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $108.33M
Last updated: Nov 17, 2026 at 11:05 AM ET
OnKure Therapeutics, Inc. (OKUR) Stock Forecast
Analysts expect OnKure Therapeutics (OKUR) to earn -$1.61 per share in the fiscal year ending Dec 31, 2026. Of 6 analysts, 5 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 2.17, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 83% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 5 | 83.3% |
| Hold | 1 | 16.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 6
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$1.61
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$1.63
- EPS consensus, revenue $1.00M
- Next report
- Mar 10, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.61 | -$1.62 to -$1.60 | 2 | N/A | N/A | 3 |
| Dec 31, 2027 | -$1.63 | -$2.08 to -$1.32 | 3 | $1.00M | N/A | 2 |
Quarterly Estimates
The EPS consensus rises from -$0.39 for the quarter ending Dec 31, 2026 to -$0.35 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.39 | -$0.43 to -$0.36 | 6 | $255000 | N/A | 5 |
| Mar 31, 2027 | -$0.35 | -$0.35 to -$0.35 | 1 | $166670 | N/A | 3 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 0 upward and 3 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 2 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$1.96.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.61 | -$1.83 | -$1.83 | -$1.83 | -$1.96 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.63 | -$1.53 | -$1.53 | -$1.53 | -$1.96 | N/A |
| Quarter ending Mar 31, 2027 | -$0.35 | -$0.31 | -$0.31 | -$0.31 | -$0.73 | N/A |
Frequently Asked Questions About OKUR
What is the OKUR stock forecast?
Consensus analyst estimates put OnKure Therapeutics's EPS at -$1.61 for the fiscal year ending Dec 31, 2026. The consensus rating from 6 analysts is Buy.
How do analysts rate OKUR stock?
Of 6 analysts covering OnKure Therapeutics, 0 rate it Strong Buy, 5 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from OKUR next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.61, with estimates from -$1.62 to -$1.60 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.63, with estimates from -$2.08 to -$1.32 from 3 analysts.
What revenue do analysts expect from OnKure Therapeutics next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.00M.
How many analysts cover OKUR?
6 analysts rate OnKure Therapeutics stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
OKUR pages: Overview, Earnings, Forecast, Financials, Competitors